Literature DB >> 12637156

p130 expression in thyroid neoplasms: its linkage with tumor size and dedifferentiation.

Yasuhiro Ito1, Hiroshi Yoshida, Takashi Uruno, Keiichi Nakano, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Tamotsu Yokozawa, Fumio Matsuzuka, Kanji Kuma, Akira Miyauchi.   

Abstract

p130 belongs to the retinoblastoma-related gene family, and its gene product works to negatively regulate cell cycle progression in the G1 phase. In this study, we investigated p130 expression in thyroid neoplasms. p130 overexpression was observed in 33.3% of follicular adenoma and 50% of follicular carcinoma and the incidences were not significantly different. In papillary carcinoma, it was overexpressed in 36.5% of cases, but in microcarcinoma, the incidence was significantly lower (14.3%). Furthermore, in anapalstic carcinoma, p130 overexpression was less frequently seen than in papillary carcinoma except for microcarcinoma and follicular carcinoma, and only 14.3% of cases overexpressed this protein. These findings suggest that: (1) reduced p130 expression may contribute to the aggressive character of anplastic carcinoma; and (2) p130 may specify the growth characteristics of microcarcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637156     DOI: 10.1016/s0304-3835(02)00627-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

1.  Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2.

Authors:  Taylor P Enrico; Wayne Stallaert; Elizaveta T Wick; Peter Ngoi; Xianxi Wang; Seth M Rubin; Nicholas G Brown; Jeremy E Purvis; Michael J Emanuele
Journal:  Elife       Date:  2021-12-01       Impact factor: 8.140

2.  Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin.

Authors:  Anna Batistatou; Konstantinos Charalabopoulos; Yukihiro Nakanishi; Constantine Vagianos; Setsuo Hirohashi; Niki J Agnantis; Chrissoula D Scopa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.